Theravance Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	109.78	107.46	64.38	57.42	51.35	55.31
Revenue Growth (YoY)	68.20%	66.92%	12.12%	11.84%	-7.17%	-23.03%
Gross Profit	109.78	107.46	64.38	57.42	51.35	55.31
Selling, General & Admin	73	73.65	69.17	70.1	67.07	99.3
Research & Development	31.79	37.41	37.64	40.62	63.39	193.66
Other Operating Expenses	7.27	-	4.51	2.74	12.84	20.14
Total Operating Expenses	112.06	111.07	111.33	113.46	143.3	313.1
Operating Income	1.35	-3.6	-46.95	-56.04	-91.96	-257.78
Interest Expense	-1.82	-2.46	-2.55	-2.35	-6.37	-8.55
Other Non-Operating Income (Expense)	87.39	135.31	4.88	9.12	5.51	1.11
Total Non-Operating Income (Expense)	85.57	132.85	2.34	6.77	-0.86	-7.44
Pretax Income	136.92	129.25	-44.61	-49.27	-92.82	-265.22
Provision for Income Taxes	35.38	23.35	11.8	5.92	178.98	-0.15
Net Income	114.54	105.9	-56.42	-55.19	872.13	-199.43
Earnings From Discontinued Operations	-	-	-	-	964.96	65.65
Net Income to Common	114.54	105.9	-56.42	-55.19	872.13	-199.43
Shares Outstanding (Basic)	51	50	49	55	74	69
Shares Outstanding (Diluted)	52	52	49	55	74	69
Shares Change (YoY)	4.59%	5.45%	-11.67%	-24.85%	5.95%	11.41%
EPS (Basic)	2.26	2.10	-1.15	-1.00	11.85	-2.87
EPS (Diluted)	2.20	2.06	-1.15	-1.00	11.85	-2.87
Shares Outstanding	51.52	51.07	49.47	48.09	65.23	74.44
Free Cash Flow	268.76	238.5	-11.87	-29.49	-187.56	-211.26
Free Cash Flow Growth	12.69%	-	-	-	-	-
Free Cash Flow Per Share	5.20	4.63	-0.24	-0.53	-2.55	-3.04
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	1.23%	-3.35%	-72.92%	-97.58%	-179.09%	-466.06%
Profit Margin	103.46%	98.54%	-87.63%	-96.11%	-180.78%	-479.24%
FCF Margin	244.82%	221.93%	-18.43%	-51.35%	-365.29%	-381.96%
EBITDA	7.05	2.04	-40.83	-49.88	-84.25	-249.2
EBITDA Margin	6.42%	1.90%	-63.41%	-86.87%	-164.09%	-450.54%
EBIT	1.35	-3.6	-46.95	-56.04	-91.96	-257.78
EBIT Margin	1.23%	-3.35%	-72.92%	-97.58%	-179.09%	-466.06%
Effective Tax Rate	25.84%	18.07%	-26.46%	-12.02%	-192.84%	0.06%

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q